GGHC
MCRB icon

Gilder Gagnon Howe & Co’s Seres Therapeutics MCRB Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-169
Closed -$24K – 410
2021
Q3 		$24K Sell
169
-120,175
-100% -$23.5M ﹤0.01% 396
2021
Q2 		$57.4M Sell
120,344
-10,064
-8% -$4.25M 0.28% 92
2021
Q1 		$53.7M Sell
130,408
-28,791
-18% -$13.3M 0.29% 95
2020
Q4 		$78M Sell
159,199
-72
-0% -$42.2K 0.39% 80
2020
Q3 		$90.2M Buy
159,271
+154,093
+2,976% +$51.2M 0.56% 58
2020
Q2 		$493K Sell
5,178
-35
-0.7% -$3.07K ﹤0.01% 253
2020
Q1 		$372K Buy
+5,213
New +$350K ﹤0.01% 225

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gilder Gagnon Howe & Co's MCRB Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 169 shares — an estimated $24K sold.

Gilder Gagnon Howe & Co first reported a position in MCRB in Q1 2020 and held it in 7 quarters. The position peaked at $90.2M in Q3 2020. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • Gilder Gagnon Howe & Co reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 169 Seres Therapeutics shares in Q4 2021, an estimated $24K.
  • Gilder Gagnon Howe & Co first reported a position in Seres Therapeutics in Q1 2020 and held it in 7 quarters.
  • Gilder Gagnon Howe & Co's Seres Therapeutics position peaked at $90.2M in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.